← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePreclinical
Cell function identification (Cell function identification)
Fondazione Policlinico Universitar…·Bronchiolitis Obliterans Syndrome …
46 trials
Overview
Program
Cell function identification
Overview
Company
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overview
Modality
CGT
Overview
Target
Bronchiolitis Obliterans Syndrome (BOS)
Overview
Indication
Bronchiolitis Obliterans Syndrome (BOS)
Overview
Phase
PRECLINICAL
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Technology
Vector
AAV-METTL14
MoA
Mechanism
target was knocked down using RNA interference, then the PrsA- or SS2-induced corresponding cells death were determined via LDH release and LIVE/DEAD staining, with its downstream pathway
MoA
Biomarker
biomarkers, namely the neutrophil-to-lymphocyte count ratio (NLCR) and platelet-to-lymphocyte count ratio (PL
PK/PD
Species
Mouse, Critically
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Mouse, Critically
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.. The identification of small molecule modulators of immune checkpoint proteins remains a significant challenge in drug discovery due to the flat, featureless nature of protein-protein interaction interfaces and the characteristically low hit rates observed…
Clinical
Safety signal
OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.. The identification of small molecule modulators of immune checkpoint proteins remains a significant challenge in drug discovery due to the flat, featureless nature of protein-protein interaction interfaces and the characteristically low hit rates observed…
Clinical
Program phase
PRECLINICAL